Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 1;46(12):530-536.
doi: 10.1097/COC.0000000000001042. Epub 2023 Sep 14.

MRI-guided Real-time Online Gated Stereotactic Body Radiation Therapy for Liver Tumors

Bhanu Prasad Venkatesulu  1 , Emily Ness  1 , Dylan Ross  1 , Anjali L Saripalli  1 , Gerard Abood  2 , Ami Badami  3 , Scott Cotler  4 , Asha Dhanarajan  3 , Lawrence M Knab  2 , Brian Lee  1 , Christopher Molvar  4 , Anil Sethi  1 , William Small Jr  1 , Tamer Refaat  1
Affiliations

MRI-guided Real-time Online Gated Stereotactic Body Radiation Therapy for Liver Tumors

Bhanu Prasad Venkatesulu et al. Am J Clin Oncol. .

Abstract

Background: Liver tumors are commonly encountered in oncology. The study aimed to assess the impact of magnetic resonance imaging (MRI)-guided stereotactic body radiation therapy (SBRT) (MRgSBRT) on disease-related outcomes and the toxicity profile.

Methods: Patients who received MRgSBRT from 2019 to 2021 for primary and metastatic liver tumors were included in this analysis. The protocol for treatment simulation included Gadoxetate disodium injection followed by a single-dimensional post-exhale MRI (0.35-T MRI linear accelerator) and computed tomography simulation. The patient demographics and treatment-related outcomes were assessed. The time-to-event curves were analyzed for freedom from local progression (FFLP) and overall survival (OS).

Results: A total of 35 patients were eligible for analysis with a median age of 70 years (range 25 to 95). The median follow-up was 19.4 months (range 1 to 37 mo). The one-year OS was 77.7%, with an estimated 3 years of 47.9%. Patients with the locally controlled disease had a better median OS of 27.8 months (95% CI [23.8-31.6]) compared with 13.5 months (95% CI [5.6-21.3], P =0.007) in patients with local disease progression. The 1-year FFLP was 95.6%, and 3-year estimated FFLP was 87.1%. Patients who received a radiation dose of biologically equivalent dose≥100 Gy had FFLP of 30.9 months (95% CI [28.7-33.1]) compared with 13.3 months (95% CI [5.3-21.3], P =0.004) in patients who received <100 Gy biologically equivalent dose.

Conclusion: MRI-guided SBRT provides optimal local control, associated with improved OS in a heavily morbid, pretreated older cohort of patients with reasonable safety profiles.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflicts of interest.

References

    1. Mahadevan A, Blanck O, Lanciano R, et al. Stereotactic Body Radiotherapy (SBRT) for liver metastasis—clinical outcomes from the international multi-institutional RSSearch® Patient Registry. Radiat Oncol. 2018;13:26.
    1. Boldrini L, Corradini S, Gani C, et al. MR-guided radiotherapy for liver malignancies. Front Oncol. 2021;11:616027.
    1. Gaya A, Camilleri P, Nash A, et al. Implementation of stereotactic MRI-Guided adaptive radiotherapy (SMART) for hepatobiliary and pancreatic cancers in the United Kingdom—fifty in five. Cureus. 2021;13:e15075.
    1. Janssen TM, Aitken K, Alongi F, et al. First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac. Tech Innov Patient Support Radiat Oncol. 2022; 22:50–54.
    1. Stanescu T, Shessel A, Carpino-Rocca C, et al. MRI-guided online adaptive stereotactic body radiation therapy of liver and pancreas tumors on an MR-linac system. Cancers (Basel). 2022;14:716.